JOHNS HOPKINS MEDICINE
JOHNS HOPKINS HEALTHCARE

Icatibant, Firazyr, Sajazir

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4**.**

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office*

Drug Information:

*Strength/Measure*_____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un
*Directions(sig)*_____ *Route of administration*_____
*Dosing frequency*_____

Send completed form to: Priority Partners Fax: 1-866-212-4756

Criteria Questions:

1. What is the prescribed drug? ❑ Firazyr ❑ Sajazir ❑ icatibant
2. What is the diagnosis?
   ❑ Hereditary angioedema (HAE) with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing
   ❑ HAE with normal C1 inhibitor confirmed by laboratory testing
   ❑ Other _____
3. What is the ICD-10 code? _____
4. Is the requested medication being used for the treatment of acute HAE attacks? ❑ Yes ❑ No
5. Will the requested medication be used in combination with any other medication used for the treatment of acute HAE attacks (e.g., Berinert, Kalbitor, Ruconest)? ❑ Yes ❑ No
6. Has the patient previously received treatment with the requested medication?
   ❑ Yes ❑ No *If No, skip to diagnosis section*
7. Has the patient experienced a reduction in severity and/or duration of attacks when the requested medication is used to treat an acute attack? ***ACTION REQUIRED: If 'Yes', please attach supporting chart note(s) demonstrating a reduction in severity and/or duration of attacks***. ❑ Yes ❑ No
8. Does the patient's attack frequency, attack severity, comorbid conditions and patient's quality of life warrant prophylactic therapy? ❑ Yes ❑ No *If No, skip to diagnosis section*
9. Has prophylactic treatment been considered*? If Yes, skip to diagnosis section* ❑ Yes ❑ No
10. Please provide a brief rationale as to why prophylactic treatment has not been considered.
    _____

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Hereditary Angioedema (HAE) with C1 Inhibitor Deficiency or Dysfunction Confirmed by Laboratory Testing

11. Does the patient have a C4 level below the lower limit of normal as defined by the laboratory performing the test prior to initiating therapy (i.e. testing at the time of diagnosis and/or prior to starting any biologic treatment)? ***ACTION REQUIRED: If 'Yes', please attach laboratory test or medical record documentation confirming low C4 level.*** ❑ Yes ❑ No ❑ Unknown
12. Which of the following conditions does the patient have (i.e. condition/testing result at the time of diagnosis and/or prior to starting any biologic treatment? ***ACTION REQUIRED: For any answer, please attach laboratory test or medical record documentation confirming C1 inhibitor functional and antigenic protein levels.***
    ❑ A C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test
    ❑ A normal C1-INH antigenic level and a low C1-INH functional level (functional C1-INH less than 50% or C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)
    ❑ Other _____

Section B: HAE with Normal C1 Inhibitor Confirmed by Laboratory Testing

13. Which of the following conditions does the patient have? ***ACTION REQUIRED: For any answer, please attach laboratory test or medical record documentation confirming C4 levels and normal C1 inhibitor. Based on the answer provided, attach genetic test or medical record documentation confirming F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation testing or chart notes confirming family history of angioedema.***
    ❑ F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation as confirmed by genetic testing
    ❑ BOTH of the following: 1) Angioedema refractory to a trial of high-dose antihistamine therapy (i.e., cetirizine at 40 mg per day or the equivalent) for at least one month AND 2) Family history of angioedema
    ❑ Other _____

Send completed form to: Priority Partners Fax: 1-866-212-4756

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076

Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com